Cardiovascular Disease

Science at Genzyme Research Areas Technology Platforms Pipeline Clinical Trials Research Grants Investigator-Sponsored Studies Animals in Research Research Publications

All Publications

Kajiwara H, Luo Z, Belanger AJ, Urabe A, Vincent KA, Akita GY, Cheng SH, Mochizuki S, Gregory RJ, Jiang C. 2009. A hypoxic inducible factor-1alpha hybrid enhances collateral development and reduces vascular leakage in diabetic rats. J Gene Med 16 Mar 2009 [Epub ahead of print].
Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, Lipshultz SE. 2008. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy Registry. Amer Heart J 155(6):998-1005.
Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J. 2008. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103(5):485-92.
Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin J-T, Marolleau J-P, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. 2008. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 117(9):1189-200.
Belanger AJ, Luo Z, Vincent KA, Akita GY, Cheng SH, Gregory RJ, Jiang C. 2007. Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor alpha/retinoid X receptor. Biochem Biophys Res Commun 364:567-572.
Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, Lurie PR, Orav EJ, Towbin JA. 2007. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: Findings from the Pediatric Cardiomyopathy Registry. Circulation 115(6):773-81.
Cox GF. 2007. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog in Pediatric Cardiology 24(1):15-25.
Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N. 2007. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 115:1234-1243.
Vincent KA, Jiang C, Boltje I, Kelly RA. 2007. Gene therapy progress and prospects: Therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther 14:781-789.
Luo Y, Jiang C, Belanger A, Akita G, Wadsworth S, Gregory R, Vincent K. 2006. A constitutively active HIF-1{alpha}/VP16 hybrid factor activates expression of the human B-Type natriuretic peptide gene. Mol Pharmacol.
Zhang M, Michael LH, Grosjean SA, Kelly RA, Carroll MC, Entman ML. 2006. The role of natural IgM in myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 41:62-67.
Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C. 2005. Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am J Physiol Cell Physiol 288:C314-320.
Donovan JM, Von Bergmann K, Setchell KD, Isaacsohn J, Pappu AS, Illingworth DR, Olson T, Burke SK. 2005. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci 50:1232-1238.
Frantz S, Bauersachs J, Kelly RA. 2005. Innate immunity and the heart. Curr Pharm Des 11:1279-1290.
Frantz S, Vincent KA, Feron O, Kelly RA. 2005. Innate immunity and angiogenesis. Circ Res 96:15-26.
Heinl-Green A, Radke PW, Munkonge FM, Frass O, Zhu J, Vincent K, Geddes DM, Alton EW. 2005. The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia. Eur Heart J 26:1327-1332.
Luo Z, Akita GY, Date T, Treleaven C, Vincent KA, Woodcock D, Cheng SH, Gregory RJ, Jiang C. 2005. Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. Circulation 111:1679-1684.
Jiang C, Yang Y-F, Cheng SH. 2004. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther 4:33-39.
Luo Z, Palasis M, Yamakawa M, Liu LX, Vincent KA, Trudell L, Akita GA, Koch WJ, Cheng SH, Gregory RJ, Jiang C. 2004. Catheter-mediated delivery of adenoviral vectors expressing beta-adrenergic receptor kinase C-terminus inhibits intimal hyperplasia and luminal stenosis in rabbit iliac arteries. J Gene Med 6:1061-1068.
Marquis JK, Dagher R, Jones M. 2004. Dietary administration of colesevelam hydrochloride does not affect fertility or reproductive performance in rats. Int J Toxicol 23:357-367.
Moore JW, Binder GA, Berry R. 2004. Prenatal diagnosis of aneuploidy and deletion 22q11.2 in fetuses with ultrasound detection of cardiac defects. Am J Obstet Gynecol 191:2068-2073.
Oyama J-i, Blais CJ, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. 2004.Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:784-789.
Date T, Luo Z, Yamakawa M, Belanger AJ, Scaria A, Cheng SH, Gregory RJ, Mochizuki S, Jiang C. 2003. Myocardial expression of baculoviral p35 alleviates doxorubicin-induced cardiomyopathy in rats. Hum Gene Ther 14:947-957.
Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C. 2003. Differential effects of membrane and soluble Fas ligand on cardiomyocytes: role in ischemia/reperfusion injury. J Mol Cell Cardiol 35:811-821.
Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD. 2003. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348:1703-1705.
Nelson BC, Pfeiffer CM, Sniegoski LT, Satterfield MB. 2003. Development and evaluation of an isotope dilution LC/MS method for the determination of total homocysteine in human plasma. Anal Chem 75:775-784.
Stewart JD, Masi TL, Cumming AE, Molnar GM, Wentworth BM, Sampath K, McPherson JM, Yaeger PC. 2003. Characterization of proliferating human skeletal muscle-derived cells in vitro: differential modulation of myoblast markers by TGF-beta2. J Cell Physiol 196:70-78.
Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, Jiang C. 2003. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 93:664-673.
Belanger AJ, Lu H, Date T, Liu LX, Vincent KA, Akita GY, Cheng SH, Gregory RJ, Jiang C. 2002. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. J Mol Cell Cardiol 34:765-774.
Chertow GM, Burke SK, Raggi P. 2002. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252.
Date T, Belanger AJ, Mochizuki S, Sullivan JA, Liu LX, Scaria A, Cheng SH, Gregory RJ, Jiang C. 2002. Adenovirus-mediated expression of p35 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activity. Cardiovasc Res 55:309-319.
Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. 2002. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 36:392-397.
Feron O, Kelly RA. 2002. Gaining respectability: Membrane-delimited, caveolar-restricted activation of ion channels. Circ Res 90:369-370.
Jiang C, Lu H, Vincent KA, Shankara S, Belanger AJ, Cheng SH, Akita GY, Kelly RA, Goldberg MA, Gregory RJ. 2002. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics 8:23-32.
Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. 2002. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701.
Liu LX, Lu H, Luo Y, Date T, Belanger AJ, Vincent KA, Akita GY, Goldberg M, Cheng SH, Gregory RJ, Jiang C. 2002. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 291:908-914.
Oyama J-I, Frantz S, Blaid CJ, Kelly RA, Bourcier T, Jogdutt B. 2002. Nitric oxide, cell death, and heart failure. Heart Fail Rev 7:327-334.
Vincent KA, Feron O, Kelly RA. 2002. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 12:362-367.

Genzyme Partnering

49 New York Avenue
Framingham, MA 01701
USA

Send email

EU Partnering

Gooimeer 10
1411 DD NAARDEN
The Netherlands
F: +31 35 699 1400

Send email

Free Drug Programs

Find out how Genzyme provides free treatment to patients in need by working with local governments, humanitarian groups, and others.

Read about our efforts

Targeting Unmet Needs

View our specialized portfolio of therapies, which provide personalized treatment for patients with rare diseases.

See our product list

Latest Press Releases

Keep up to date by reading the latest press releases for Genzyme.

Jobs at Genzyme

Explore exciting opportunities in research, development, and all other aspects of biotechnology.

Search jobs now

infoBox